Ardelyx Inc Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)0.82 Intrinsic Value $15.93median of 2 methodsbased on filings through 30 Jun 2026 Market Price $3.42Price as of 30 Sep 2026 Significantly undervaluedIntrinsic value is 366% above the market price −50% · IV below pricenear fair value ±15%IV above price · +50% marker beyond scale (+366%) Data confidence Sign in to view data confidence Market Cap $883M Enterprise Value $1B Shares Outstanding 248.7M diluted Next Earnings Date1 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Ardelyx is a high-growth commercial-stage biopharmaceutical company with a strong dual-product portfolio consisting of IBSRELA (for IBS-C) and XPHOZAH (for hyperphosphatemia). The company is demonstrating robust top-line growth, driven by a 58% year-over-year increase in IBSRELA sales in Q1 2026. With a clear path to reaching $1 billion in annual IBSRELA revenue by 2029 and significant pipeline optionality from the Phase 3 ACCEL trial in chronic idiopathic constipation, Ardelyx represents a compelling growth opportunity. While near-term profitability remains a challenge due to elevated commercialization and R&D expenses, its strong cash position of $238.1 million and recent debt refinancing provide a solid financial runway. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$8.00 Mean target$13.00 High · most bullish analyst$18.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $8.00 Medicare Part D reimbursement challenges severely restrict patient access to XPHOZAH, causing sales to fall short of the FY 2026 guidance. IBSRELA growth slows down due to intense competition in the IBS-C space. Operational expenses, particularly SG&A and R&D for the ACCEL trial, continue to rise, accelerating cash burn and forcing the company to seek dilutive equity financing or draw heavily on its debt facility, delaying the timeline to profitability beyond 2029. Base CaseCentral scenario $13.00 Matches the consensus meanIBSRELA continues its steady commercial ramp, meeting the reiterated FY 2026 guidance of $410 million to $430 million and progressing toward its $1 billion peak sales target by 2029. XPHOZAH sales remain stable within the guided range of $110 million to $120 million for FY 2026, supported by growth in non-Medicare channels. The ACCEL Phase 3 trial completes enrollment by the end of 2026. The company achieves operating breakeven by late 2027 or early 2028 as commercial expenses stabilize relative to revenue growth. Bull CaseUpside scenario $18.00 IBSRELA adoption accelerates beyond expectations, capturing a larger share of the IBS-C market and achieving the $1 billion peak sales target ahead of the 2029 timeline. Simultaneously, the Phase 3 ACCEL trial for chronic idiopathic constipation (CIC) delivers positive top-line data, potentially tripling IBSRELA's addressable market. XPHOZAH successfully navigates Medicare reimbursement hurdles, driving rapid adoption in the dialysis market. Operating leverage kicks in sooner than expected, leading to GAAP profitability by late 2027. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |